- Obesity requires chronic, long-term pharmacologic management.
- Semaglutide and tirzepatide received strong recommendations.
- Glucagon-like peptide-1–based therapies improve cardiometabolic outcomes beyond weight loss.
- Continue medications to maintain weight loss and benefits.
- Access and cost barriers remain major limitations.
Source: Obesity
